© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
In this second of a six-part series, the biggest concern is short supply.
The State of the Industry survey was conducted in October and November before the FDA granted emergency use authorizations for the Pfizer-BioNTech and the Moderna vaccines. Roughly one-third (32%) of the respondents indicated that they were extremely concerned about the vaccine being in short supply, and 41% were indicated that level of concern about a large percentage of American not getting vaccinated.